Paratek's Omadacycline Get US Panel OK, But CABP Mortality Remains Concern
Executive Summary
Most FDA advisory committee members say potential mortality issue seen in community acquired bacterial pneumonia patients can be addressed postmarket.
You may also be interested in...
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
The latest drug development news and highlights from our US FDA Performance Tracker.
Paratek's Antibiotic Nuzyra Survived 20 Years – Now For The US Launch
Company still mulling pricing for broad-spectrum antibiotic Nuzyra (omadacycline), which is set to launch in the US in the first quarter, following FDA approval Oct. 2.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.